RE:M P Email TodayEmail from Theralase today focusses on our advantages vs CG Oncology.
As you are most likely aware, CG Oncology reported out last Thursday and although their clinical data was strong (Initial CR of 74.5%, duration of CR at 12 months of 50.0% and at 24 months 30.5%), they were required to pre-screen their patients to a sub group that only ~25% of the entire patient population meet to acheive these results.
Theralase® is able to address the entire BCG-Unresponsive NMIBC CIS population with durations of CR equivalent or superior to CG Oncology.
...nicely done...concise...and easy to understand...
Cheers, judgesmails